Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience.

Caloglu M, Yurut-Caloglu V, Karagol H, Bayir-Angin G, Turan FN, Uzal C.

J BUON. 2009 Apr-Jun;14(2):211-8.

PMID:
19650168
2.

Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.

Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur Altinors M.

J Neurosurg Sci. 2010 Mar;54(1):7-19.

PMID:
20436394
3.

Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, Delfini R.

Tumori. 2007 May-Jun;93(3):248-56.

4.

Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.

Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, Rödel C.

Radiother Oncol. 2010 Dec;97(3):382-6. doi: 10.1016/j.radonc.2010.06.014. Epub 2010 Sep 17.

PMID:
20850883
5.

Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.

Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C.

Strahlenther Onkol. 2011 Nov;187(11):722-8. doi: 10.1007/s00066-011-2230-x. Epub 2011 Oct 28.

PMID:
22037649
6.

Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.

Wang TJ, Jani A, Estrada JP, Ung TH, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Isaacson SR, Cheng SK, McKhann GM 2nd, Bruce JN, Lassman AB, Sisti MB.

Neurosurgery. 2016 May;78(5):676-82. doi: 10.1227/NEU.0000000000001036.

PMID:
26440447
7.

Primary glioblastoma multiforme in younger patients: a single-institution experience.

Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M.

Tumori. 2006 Sep-Oct;92(5):407-11.

PMID:
17168433
8.

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C.

J Neurosurg. 2016 Apr;124(4):998-1007. doi: 10.3171/2015.4.JNS142200. Epub 2015 Oct 9.

PMID:
26452121
9.

Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.

Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, Pace A, Giangaspero F, Bozzao A, Enrici RM.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):109-15. doi: 10.1016/j.ijrobp.2014.09.013. Epub 2014 Oct 25.

PMID:
25442339
10.
11.

Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.

Ciammella P, Galeandro M, D'Abbiero N, Podgornii A, Pisanello A, Botti A, Cagni E, Iori M, Iotti C.

Clin Neurol Neurosurg. 2013 Sep;115(9):1609-14. doi: 10.1016/j.clineuro.2013.02.001. Epub 2013 Feb 26.

PMID:
23453151
12.

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R.

J Clin Oncol. 2006 Jun 1;24(16):2563-9.

PMID:
16735709
13.

Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients.

Okumus NO, Gursel B, Meydan D, Ozdemir O, Odabas E, Gonullu G.

Ann Saudi Med. 2012 May-Jun;32(3):250-5. doi: 10.5144/0256-4947.2012.250.

14.

Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.

Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR.

J Neurooncol. 2012 Apr;107(2):395-405. doi: 10.1007/s11060-011-0766-3. Epub 2011 Nov 22. Review.

PMID:
22105851
15.

Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.

Badiyan SN, Markovina S, Simpson JR, Robinson CG, DeWees T, Tran DD, Linette G, Jalalizadeh R, Dacey R, Rich KM, Chicoine MR, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):877-85. doi: 10.1016/j.ijrobp.2014.07.014. Epub 2014 Sep 23.

PMID:
25257812
16.

Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.

Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):802-810. doi: 10.1016/j.ijrobp.2017.02.028. Epub 2017 Feb 21.

PMID:
28602411
17.

Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.

Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.

Anticancer Res. 2003 Nov-Dec;23(6D):5159-64.

PMID:
14981983
18.

Treatment options and outcomes for glioblastoma in the elderly patient.

Arvold ND, Reardon DA.

Clin Interv Aging. 2014 Feb 21;9:357-67. doi: 10.2147/CIA.S44259. eCollection 2014. Review.

19.

Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.

Gzell C, Wheeler H, Guo L, Kastelan M, Back M.

J Neurooncol. 2014 Aug;119(1):187-96. doi: 10.1007/s11060-014-1472-8. Epub 2014 May 15.

PMID:
24830984
20.

A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?

Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, O'Neill B, Faul C.

Br J Radiol. 2012 Sep;85(1017):e729-33. doi: 10.1259/bjr/83796755. Epub 2012 Jan 3.

Supplemental Content

Support Center